Research programme: antibodies to infectious agents - Affitech
Latest Information Update: 18 Jan 2011
At a glance
- Originator Affitech AS
- Class Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal infections; Varicella zoster virus infections
Most Recent Events
- 17 Aug 2005 This programme is still in active development - (BIO-2005)
- 28 Jun 2004 Varicella zoster virus and Neisseria meningitides antibody products are available for licensing (http://www.affitech.com)
- 28 Jun 2004 Preclinical trials in Meningococcal infections in Norway (Injection)